Canterbury DHB

Context

Further Reading

  1. Arber DA, et al. (2016). The 2016 revision to the World Health Organisation of Myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391-405.
  2. Cazzola M (2016). Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues Blood 2016 127:2361-2364; doi: https://doi.org/10.1182.
  3. Campbell PJ, Green AR (2005). Management of Polycythemia Vera and Essential Thrombocythemia. Hematology 2005(1): 201-208.
  4. Beer PA, Green AR (2009). Pathogenesis and management of essential thrombocythemia. Hematology 2009(1): 621-628.
  5. Barbui T, et al. (2018). The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018 Feb 9;8(2):15.
  6. Barbui T, et al. (2011). Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J. Clin. Oncol. 29, 3179–3184.
  7. Beer P (2011). How I treat essential thrombocythemia. Blood. 17:1472-1482.
  8. Harrison CN, et al. (2005). Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia. N. Engl. J. Med. 2005;353:33–45.
  9. Tefferi A, Barbui T (2013). Personalized management of essential thrombocythemia-application of recent evidence to clinical practice. Leukemia 27(8): 1617-1620.
  10. Tefferi A (2013). Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 88(6): 507-516.
  11. Wolanskyj AP, et al. (2006). Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 81(2):159-166.

About this Canterbury DHB document (536464):

Document Owner:

Andrew Butler (see Who's Who)

Issue Date:

August 2018

Next Review:

April 2021

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 536464